Gynecologic Oncology Reports

metrics 2024

Empowering collaboration in gynecologic oncology.

Introduction

Gynecologic Oncology Reports is a pivotal interdisciplinary journal published by Elsevier Science Inc. that has been dedicated to advancing the understanding of women's health since its inception in 2014. This Open Access journal, available to a global audience, facilitates the dissemination of high-quality research in the fields of gynecology and oncology, allowing for the free exchange of knowledge and fostering collaboration among researchers, clinicians, and students. With an impact factor reflective of its commitment to clinical relevance, Gynecologic Oncology Reports holds a Q3 ranking in both obstetrics and gynecology as well as oncology categories, contributing to its visibility and the prestige of published work. Situated in the Netherlands and operating within an open-access framework, it ensures that critical findings and advancements reach a broad readership. The journal serves as a vital resource for those aiming to stay at the forefront of gynecologic oncology, promoting improved patient outcomes through cutting-edge research. As it converges towards its 10th anniversary in 2024, Gynecologic Oncology Reports continues to be an essential platform for scholarly communication in this important field.

Metrics 2024

SCIMAGO Journal Rank0.40
Journal Impact Factor1.20
Journal Impact Factor (5 years)1.20
H-Index25
Journal IF Without Self1.20
Eigen Factor0.00
Normal Eigen Factor0.44
Influence0.35
Immediacy Index0.20
Cited Half Life3.60
Citing Half Life7.10
JCI0.46
Total Documents1390
WOS Total Citations1161
SCIMAGO Total Citations3461
SCIMAGO SELF Citations162
Scopus Journal Rank0.40
Cites / Document (2 Years)1.15
Cites / Document (3 Years)1.20
Cites / Document (4 Years)1.17

Metrics History

Rank 2024

Scopus

Obstetrics and Gynecology in Medicine
Rank #117/209
Percentile 44.02
Quartile Q3
Oncology in Medicine
Rank #272/404
Percentile 32.67
Quartile Q3

IF (Web Of Science)

OBSTETRICS & GYNECOLOGY
Rank 98/136
Percentile 28.30
Quartile Q3

JCI (Web Of Science)

OBSTETRICS & GYNECOLOGY
Rank 97/136
Percentile 28.68
Quartile Q3

Quartile History

Similar Journals

Journal of Thoracic Oncology

Unveiling the Science Behind Thoracic Cancers
Publisher: ELSEVIER SCIENCE INCISSN: 1556-0864Frequency: 12 issues/year

Journal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.

Journal of Cancer

Connecting researchers to transform cancer care.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

Revista Colombiana de Cancerologia

Innovating Cancer Care: Insights from Colombia
Publisher: INST NACIONAL CANCEROLOGIAISSN: 0123-9015Frequency: 4 issues/year

Revista Colombiana de Cancerologia is a premier journal dedicated to advancing the field of oncology in Colombia and beyond. Published by the Instituto Nacional de Cancerología, this journal serves as a vital platform for the dissemination of high-quality research, comprehensive reviews, and innovative methodologies pertinent to cancer research and treatment. With an ISSN of 0123-9015 and E-ISSN 2346-0199, it aims to engage a diverse audience, including researchers, healthcare professionals, and students, fostering collaboration and knowledge sharing within the oncology community. Although specific metrics such as impact factors and H-index are currently unavailable, the journal is committed to maintaining high academic standards and encouraging open access to vital oncological insights. The Revista Colombiana de Cancerologia is positioned as an essential resource for those interested in the latest advancements in cancer care, prevention, and research methodologies, making significant contributions to the understanding and management of cancer.

Molecular and Clinical Oncology

Connecting researchers to revolutionize cancer treatment.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

LANCET ONCOLOGY

Advancing cancer research for a healthier tomorrow.
Publisher: ELSEVIER SCIENCE INCISSN: 1470-2045Frequency: 12 issues/year

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

Leukemia Research Reports

Pioneering open access to vital leukemia insights.
Publisher: ELSEVIER ADVANCED TECHNOLOGYISSN: 2213-0489Frequency: 2 issues/year

Leukemia Research Reports, published by Elsevier Advanced Technology, is a prominent open-access journal dedicated to the latest advancements in the field of hematology and oncology. Since its launch in 2012, this journal has been a vital resource for researchers, healthcare professionals, and students aiming to disseminate and access high-quality research articles focused on various aspects of leukemia and related blood disorders. With an impact factor indicative of its significance in the field, Leukemia Research Reports currently holds a Q3 quartile ranking in both Hematology and Oncology, and is included in key databases such as Scopus. The journal not only embraces a commitment to open access, ensuring that research is freely available, but also actively promotes collaborations that strive to enhance our understanding and treatment of leukemia. Based in the United Kingdom, this journal continues to play a crucial role in fostering innovation and knowledge sharing within the medical community.

Clinical Genitourinary Cancer

Pioneering discoveries for improved patient outcomes.
Publisher: CIG MEDIA GROUP, LPISSN: 1558-7673Frequency: 6 issues/year

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

CURRENT PROBLEMS IN CANCER

Transforming Knowledge: Navigating Contemporary Challenges in Oncology
Publisher: MOSBY-ELSEVIERISSN: 0147-0272Frequency: 6 issues/year

CURRENT PROBLEMS IN CANCER is an esteemed journal published by MOSBY-ELSEVIER, dedicated to advancing the field of oncology and cancer research. With an ISSN of 0147-0272 and an E-ISSN of 1535-6345, it has been a vital resource for over four decades, converging years of expertise from 1976 to 2024. The journal is recognized for its impactful contribution to the field, currently holding a Q3 ranking in Cancer Research and a Q2 ranking in Oncology, reflecting its importance in disseminating significant advancements and discussions in the field. It is ranked #164 out of 404 in Medicine _ Oncology and #131 out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research on Scopus, indicating its relevance and reach among academic circles. Although it does not offer open access, the journal remains a crucial platform for researchers and professionals seeking to explore contemporary issues in cancer treatment and management. With its commitment to quality and innovation, CURRENT PROBLEMS IN CANCER serves as an essential conduit for knowledge sharing and research development in oncology and cancer science.

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Shaping the Future of Reproductive Medicine and Care
Publisher: MOSBY-ELSEVIERISSN: 0002-9378Frequency: 12 issues/year

The American Journal of Obstetrics and Gynecology, established in 1920 and published by Mosby-Elsevier, stands as a premier platform for the dissemination of critical research in the field of obstetrics and gynecology. With an impressive Scopus rank of #2 out of 209 journals in its category, placing it in the 99th percentile, this journal is recognized for its significant contributions to clinical practice and academia, as evidenced by its Q1 quartile status for 2023. Aimed at researchers, healthcare professionals, and students, the journal features a wide array of articles addressing contemporary issues, innovative research findings, and evolving practices in women's health and reproductive medicine. Although it does not currently offer open access options, it remains a vital resource for those seeking in-depth analysis and insights within this crucial medical specialty. By bridging the gap between research and clinical implementation, the American Journal of Obstetrics and Gynecology continues to play a pivotal role in shaping the future of obstetric and gynecologic care.

Journal of Gynecologic Oncology

Advancing Knowledge in Women's Cancer Care
Publisher: KOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPYISSN: 2005-0380Frequency: 4 issues/year

The Journal of Gynecologic Oncology, published by the Korean Society of Gynecology Oncology & Colposcopy, stands as a premier open access platform since 2011, dedicated to advancing the field of gynecologic oncology. With an ISSN of 2005-0380 and an E-ISSN of 2005-0399, this esteemed journal showcases high-quality research that drives innovation in treatment and care for women affected by gynecologic cancers. Based in South Korea, the journal spans an impressive timeline from 2009 to 2024 and holds a distinguished Q1 ranking in both Medicine (Miscellaneous) and Obstetrics and Gynecology, emphasizing its vital contributions to these fields. The journal is recognized for its rigorous peer-review process and is indexed in Scopus, with notable rankings of #35/209 and #128/404 in Obstetrics and Gynecology and Oncology respectively. As a vital resource for researchers, clinicians, and students alike, it aims to disseminate impactful findings that enhance patient care and foster collaboration across international boundaries.